BenevolentAI

BenevolentAI is a global pioneer in applying artificial intelligence and machine learning to drug discovery and development. Founded in 2013 and headquartered in London, the company has built a powerful AI-driven platform called the Benevolent Platform™ that can analyze vast amounts of biomedical data to uncover new insights into disease biology and identify novel drug targets. BenevolentAI combines AI technology with scientific expertise to discover and develop new treatments for complex diseases across multiple therapeutic areas.

The Benevolent Platform integrates vast biomedical data to provide a multidimensional representation of human biology across diseases. The company employs AI to augment human intelligence, enabling scientists to better understand disease mechanisms, discover novel drug targets, and make decisions with greater confidence to improve the probability of clinical success.

BenevolentAI offers end-to-end drug discovery capabilities, spanning the entire drug discovery and development process, applicable to any therapeutic area or drug modality. Their core AI technology, the BenAI Engine, ingests, organizes, and leverages biomedical data for a nuanced understanding of disease biology. The company fosters true collaboration between scientists and technologists to redefine how drugs are discovered and developed.